Opportunities in Evidence Generation for Tumor-agnostic Targeted Therapies to Better Support Health Technology Assessments in Europe
Tumor-agnostic therapies are among the most challenging for regulators and health technology assessment (HTA) bodies to assess. Uncertainty in evidence packages, caused by factors such as small heterogeneous populations, are not typically an issue with tumor-specific drugs. This whitepaper explores how wider use of Real World Evidence can support faster and more sustainable access to patients.